AstraZeneca & Daiichi Sankyo Report the P-III (TROPION-Lung01) Study Results of Datopotamab Deruxtecan (Dato-DXd) to Treat Advanced Non-Squamous NSCLC
Shots:
- The P-III (TROPION-Lung01) study assesses Dato-DXd's (6mg/kg) safety & efficacy vs docetaxel (75mg/m^2) to treat locally advanced/metastatic NSCLC adults with/without actionable genomic alterations, needing systemic therapy after prior treatment
- Results depicted that in the overall population, high-level OS data favored Dato-DXd but was not significant while in non-squamous NSCLC patients, improved OS was seen. This final OS analysis is supported by PFS data showing improvement & a clinically meaningful benefit in non-squamous NSCLC patients (highlighted at ESMO’23)
- The data will form the basis of regulatory applications, under ongoing review worldwide, for the above indication and will be featured at future conferences
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca and Daiichi Sankyo Report the US FDA’s Acceptance of BLA for Datopotamab Deruxtecan (Dato-DXd) to Treat Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
